Doxazosin Tablet
Product Images NDC 51655-476

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 51655-476). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 476 52)

Label (51655 476 52)
Doxazosin Tablets, USP 1 mg tablet bottle label. The label indicates a 30 tablet count, prescription only, with storage instructions and repackaging details by Northwind Pharmaceuticals. It includes a barcode and QR code, along with lot, expiration, and serial number placeholders.*
FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Doxazosin-structure.jpg (Doxazosin Structure)
Chemical structure of doxazosin, illustrating its molecular components including methoxy groups, piperazine ring, and a benzodioxane moiety, consistent with the drug doxazosin mesylate.*
FDA Label Image

Figure1.jpg (Figure1)

Figure1.jpg (Figure1)
This image contains two line graphs comparing Doxazosin tablets 1 mg to placebo. The left graph shows mean change in total symptom score from baseline over 14 weeks, with Doxazosin demonstrating greater symptom improvement than placebo. The right graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline over 14 weeks, with Doxazosin showing a higher increase than placebo. Statistical significance is indicated for several time points.*
FDA Label Image

Table3.jpg (Table3)

Table3.jpg (Table3)
Table summarizes effectiveness data from placebo-controlled trials for Doxazosin, showing symptom scores and maximum flow rate changes across three studies. It includes mean baseline values and changes for placebo and various Doxazosin doses, along with a bar graph illustrating maximum flow rate and symptom score differences in Study 2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.